Populations | Phase 1 | Phase 2 | Registrational | Approved | Current Status |
---|---|---|---|---|---|
Advanced Malignant PEComa AMPECT Clinical Trial | Single Agent | First FDA approved therapy for advanced malignant PEComa | |||
![]() | TSC1 Arm, Single Agent | Tumor-agnostic pivotal study with independent arms for TSC1 and TSC2 inactivating alterations; open for enrollment | |||
Tumor-agnostic TSC1/TSC2 Inactivating Alterations | TSC2 Arm, Single Agent | ||||
Advanced solid tumors or NSCLC with KRASG12C mutation (Phase 1/2) | nab-sirolimus + adagrasib | Collaboration ongoing with ![]() |
Drug | Indication | Stage | Advanced Malignant PEComa AMPECT Clinical Trial First FDA approved therapy for advanced malignant PEComa |
Single Agent | Current Status |
---|---|---|
![]() Tumor-agnostic pivotal study with independent arms for TSC1 and TSC2 inactivating alterations; open for enrollment |
TSC1 Arm, Single Agent | Approved |
Tumor-agnostic TSC1/TSC2 Inactivating Alterations | TSC2 Arm, Single Agent | Approved |
Advanced solid tumors or NSCLC with KRASG12C mutation (Phase 1/2) Collaboration ongoing with ![]() |
nab-sirolimus + adagrasib | Phase 2 |